6.63
前日終値:
$6.18
開ける:
$6.18
24時間の取引高:
1.85M
Relative Volume:
1.68
時価総額:
$675.70M
収益:
当期純損益:
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
1週間 パフォーマンス:
+5.24%
1か月 パフォーマンス:
+7.46%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
Starling Oncology, Inc. Common Stock Stock (STLN) Company Profile
Compare STLN vs HCA, THC, EHC, DVA, FMS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
STLN
Starling Oncology, Inc. Common Stock
|
6.63 | 675.70M | 0 | 0 | 0 | 0.00 |
|
HCA
Hca Healthcare Inc
|
458.38 | 99.24B | 76.39B | 7.81B | 7.93B | 29.08 |
|
THC
Tenet Healthcare Corp
|
268.77 | 21.64B | 21.46B | 2.65B | 3.35B | 19.23 |
|
EHC
Encompass Health Corp
|
125.02 | 12.33B | 6.07B | 793.80M | 464.40M | 5.9914 |
|
DVA
Davita Inc
|
181.52 | 11.58B | 13.84B | 1.10B | 1.49B | 10.42 |
|
FMS
Fresenius Medical Care Ag Adr
|
21.21 | 11.29B | 22.44B | 1.35B | 2.03B | 1.9002 |
Starling Oncology, Inc. Common Stock Stock (STLN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-07-06 | 開始されました | Lake Street | Buy |
| 2025-11-25 | 開始されました | Needham | Buy |
| 2025-07-23 | 開始されました | Noble Capital Markets | Outperform |
| 2025-07-16 | 開始されました | B. Riley Securities | Buy |
| 2025-05-15 | 開始されました | BTIG Research | Buy |
| 2024-02-26 | 再開されました | Jefferies | Buy |
| 2022-09-14 | 開始されました | Guggenheim | Buy |
| 2022-08-15 | 開始されました | Jefferies | Buy |
すべてを表示
Starling Oncology, Inc. Common Stock (STLN) 最新ニュース
Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation - The Manila Times
UMH PROPERTIES, INC. DECLARES COMMON AND PREFERRED DIVIDENDS - The Manila Times
ARMOUR Residential REIT, Inc. Confirms October 2026 Common Share and Q4 2026 Series C Preferred Share Dividends - The Manila Times
Compass Diversified Declares Third Quarter 2026 Distributions on Series A, B and C Preferred Shares - The Manila Times
Antelope Enterprise Holdings Limited Announces $100 Million 'At-the-Market' Equity Offering Program - The Manila Times
Nutriband Marks Five Years on NasdaqCEO Letter to Shareholders - The Manila Times
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation - www.marketscreener.com
Starling Oncology, Inc.(NasdaqCM:STLN) added to S&P Health Care Services Select Industry Index - marketscreener.com
Income Statement - Intellectia AI
3 Growth Companies With High Insider Ownership Growing Earnings Up To 132% - simplywall.st
Vice Chairman Bradford Hively Sold A Bunch Of Shares In Starling Oncology - Simply Wall Street
Starling Oncology (STLN) director sells 298K shares under 10b5-1 plan - Stock Titan
Nearly $2M in Starling Oncology (STLN) stock planned for director sale - Stock Titan
Starling Oncology (TOI) holder pairs 12K-share buy with call option sale - Stock Titan
Starling Oncology launches platform for treatment authorization - Investing.com
Starling Oncology Company Profile & Introduction - Moomoo
Starling Oncology And 2 Other Growth Stocks Insiders Are Backing - simplywall.st
US$9.00That's What Analysts Think Starling Oncology, Inc. (NASDAQ:STLN) Is Worth After These Results - simplywall.st
Starling Oncology (STLN) Stock Rerates On Cash Gains As Margin Risks Linger - simplywall.st
Oncology Institute (STLN) Stock Price, News & Analysis $STLN - marketbeat.com
Starling Oncology, Inc.STLNStock Price Today - Zacks Investment Research
The Oncology Institute, Inc. (STLN) Stock Price, News, Quote & History - Yahoo! Finance Canada
What date does Starling Oncology, Inc.'s (STLN) report EarningsEarnings Calendar & Announcement - zacks.com
Earnings call transcript: Starling Oncology Q2 2026 revenue tops forecast, stock jumps - Investing.com
Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance - GlobeNewswire
Diluted net income available to common stockholders of Starling Oncology, Inc. – NASDAQ:STLN - TradingView
The Oncology Institute Rebrands as Starling Oncology - Yahoo Finance
The Oncology Institute, Inc. will Change its Ticker to STLN from TOI - marketscreener.com
The Oncology Institute Reports Fourth Quarter and Full Year 2025 Financial Results and Guidance for 2026 - GlobeNewswire
The Oncology Institute (TOI) Stock Price, News & Analysis - Stock Titan
The Oncology Institute Warrant (TOIIW) Stock Price, News & Analysis - Stock Titan
The Oncology Institute announces $110 million strategic - GlobeNewswire
P3 Health Partners Inc. (PIIIW) Stock Price, News, Quote & History - Yahoo! Finance Canada
DFP Healthcare Acquisitions Corp. Announces Proposed Business Combination With The Oncology Institute - Business Wire
Starling Oncology, Inc. Common Stock (STLN) 財務データ
Starling Oncology, Inc. Common Stock (STLN) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Starling Oncology, Inc. Common Stock (STLN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| BRADFORD HIVELY | Director |
Aug 21 '26 |
Proposed Sale |
6.54 |
298,853 |
1,954,499 |
0 |
| Chernett Jorey | 10% Owner |
Aug 14 '26 |
Buy |
6.54 |
12,000 |
78,480 |
10,660,858 |
| Chernett Jorey | 10% Owner |
Jul 21 '26 |
Buy |
5.27 |
18,000 |
94,860 |
10,648,858 |
| Podnos Yale | Chief Medical Officer |
Jul 14 '26 |
Option Exercise |
1.90 |
23,452 |
44,567 |
277,501 |
| Podnos Yale | Chief Medical Officer |
Jul 14 '26 |
Sale |
6.41 |
23,452 |
150,340 |
259,527 |
| YALE PODNOS | Officer |
Jul 14 '26 |
Proposed Sale |
6.25 |
23,452 |
146,575 |
0 |
| Chernett Jorey | 10% Owner |
Jul 10 '26 |
Buy |
5.85 |
15,000 |
87,750 |
10,630,858 |
| Chernett Jorey | 10% Owner |
Jun 23 '26 |
Buy |
5.02 |
18,000 |
90,360 |
10,615,858 |
| Podnos Yale | Chief Medical Officer |
Jun 08 '26 |
Sale |
5.38 |
23,451 |
126,094 |
259,527 |
| YALE PODNOS | Officer |
Jun 08 '26 |
Proposed Sale |
4.87 |
23,451 |
114,206 |
0 |
大文字化:
|
ボリューム (24 時間):